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The liver is morphologically and functionally modulated by sex hormones. Long-term use of oral
contraceptives and androgenic steroids can induce benign and malignant hepatocellular tumors.
Hepatocellular carcinoma (HCC) is more prevalent in men than in women. The role of sex hormones
and their receptors in the development ofHCC was reviewed. Some HCCs may be androgen dependent
but others may be estrogen or even both dependent. Further studies are mandatory in order to utilize
such characteristics of HCC for an effective prophylaxis and therapy of this tumor.
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Cirrhosis of the liver is frequently associated with hepatocellular carcinoma (HCC).
It is well known that cirrhotic male patients, particularly th6se with alcoholic
cirrhosis, have impaired function of the hypothalamic-pituitary-gonadal axis 1. All
over the world, HCC is more prevalent in men than in women. This is especially
true in patients with cirrhosis and in the areas where HCC is common. Such male
predominance of HCC may be related to sex hormone imbalance2. On the other
hand, it is undeniable that long-term use of oral contraceptives induces not only
benign but malignant tumors of the liver. Also, androgenic anabolic steroids,
especially 17-alkyl-substituted steroids, seem to be related to the development of
liver neoplasms including HCC. These facts raise the question; what is the genuine
role of sex hormones in hepatocarcinogenesis in experimental animals and particu-
larly in humans?
Liver Tumors and Sex Steroid Administration
The effect of sex hormones on liver function and morphologic features has been
pointed out over the past two decades. It is generally accepted that the liver is one
of the target organs for estrogens. Since the first report by Baum et al. 3, a possible
correlation of estrogens with the development of hepatic neoplasms has been
suggested by numerous reports of oral contraceptive-associated focal nodular
hyperplasia (FNH) or liver cell adenoma. Malignant transformation has also been
reported in such patients. In addition, withdrawal of oral contraceptives occasio-
nally induces regression of the drug induced hepatic tumors4-6. According to the2 N. NAGASUE AND H. KOHNO
recent articles by Neuberger et al. and Forman et al., the use of contraceptive pills
for longer than 8 years is associated with a 20-fold increased risk of HCC.
On the other hand, the administration of exogenous androgens, particularly 17-
a-alkylated androgens, causes various hepatic lesions such as dilation of biliary
canaliculi, loss of canalicular villi, peliosis hepatis, adenoma, and HCC9. Such
changes occur less frequently with non-17-a-alkylated androgens. It is noteworthy
that synthetic estrogen and progestogen used for pills have a similar chemical
structure to androgenic steroids.
Although most carcinogens can be shown to be mutagenic in vitro, this has not
been demonstrated for estrogens1. The Committee on Safety of Medicine (Lon-
don) reported a tumorigenic action of synthetic estrogens in male rats but not in
female rats1. Reznik-Schuller
2 found the development of liver tumors (hepatocel-
lular adenomas, carcinomas, and cholangiocarcinoma) in 29% of male European
hamsters treated with diethylstilbestrol (DES). This seems to be the first report
showing that estrogens alone can be carcinogenic. Other authors have suggested
that estrogens promote the effect of carcinogens3-5. There are several groups in
Japan who have extensively studied this problem. Sumi et al.
6 initially found a
synergistic effect of DES and carcinogens on the development of liver tumors in
male WF rats. Later, they have found that DES itself has a direct carcinogenic
effect on the liver and that this effect is not mediated by prolactin7. Higashi et al.
8
in 1980 reported that synthetic estrogen and progestogen could induce HCC in
female Wistar rats.
Despite a considerable number of reports on androgenic steroid-induced hepatic
tumors, there is limited evidence-for a direct etiologic relationship between
administration of the drugs and HCC in humans 19. Many years ago, Morris et al.2
found that in a hepatic carcinogenesis model in rats with 2-diacetylaminofluorene
HCC occurs more frequently in intact males and castrated females treated with
testosterone than in intact females, castrated males, castrated females, and cas-
trated males treated with DES. Whether or not androgenic steroids are carcinoge-
nic remains to be elucidated.
Sex Hormone Receptors in HCC
It is theoretically assumed that the tumorigenic effect of estrogens may be through
an estrogen receptor (ER). The presence of ER in human liver was first found by
Duffy and Dully
2 in 1978. Friedman et al. 22 estimated ER levels in human HCCs.
The titer of ER in HCC taken from 5 male adults ranged from 0.9 to 6.4 fmol/mg
cytosol protein. We have measured ER of HCC in 30 adult patients23. ERs were
present in 12 (40%) tumors. Since 29 were male in that study, we next assayed the
receptor in 19 women24. ERs were detected in 7 of them (37%). Ohnishi et al.2
found the receptor in only one of 6 HCCs. At present, it is not well known if the
presence of ER in HCC is really related to the development and growth of the
tumor in humans. Li and Li
26 suggested a possibly important role of ER in
hepatocarcinogenesis since a higher value of both cytosolic and nuclear ERs in
hamster livers was observed when the regimen of DES and a-naphthoflavon was
made more tumorigenic. Considering this and previously described experimental
and clinical studies, ERs in the liver or HCC may also play a role in human hepatic
carcinogenesis.
It has long been believed that human liver is not a target organ for androgen. InCARCINOMA AND SEX HORMONES 3
1985, we first observed that normal human liver possesses androgen receptors
(AR)27. Immediately after our report, Bannister et al.
28 presented a similar
observation. Iqbal et al.
29 were the first to find ARs in human HCC. We have also
shown that ARs are present in 74% of male and 37% of female HCCs24’27. In
addition, the titers were significantly higher in HCC than in the surrounding liver
parenchyma. A very similar result was presented by Ohnishi et al. 25. We thereafter
investigated, with positive results, if extrincically given testosterones were taken up
by AR in HCC using autoradiographic techniques. All over the world, HCC is
more prevalent in males than it is in females31. This is especially true in patients
with liver cirrhosis32. Male predominance is usually explained by the fact that
alcoholism, chronic liver disease, and in particular chronic hepatitis B infection are
more prevalent among males. In the light of our serial receptor studies, however,
we have suggested that some, if not all, human HCC may be androgen-dependent.
Such a speculation is supported by our clinical results which will be described in the
next section.
Several investigative groups have shown that high titers of progesterone receptor
(PgR) are present in FNH and liver cell adenoma whether or not they are induced
by oral contraceptives33-35. Demenes et al.
36 found a similar result in hepatoblas-
toma. However, very little is known of whether PgR is present in HCC or not22’34.
We estimated PgR as well as AR and ER in 22 consecutive patients with HCC37.
PgR was considered to exist when the titer was higher than 1.0 fmol/mg of protein.
The receptor was detected in the cytosol of HCC in 4 patients (18.2%), and the
titers were low ranging from 1.1 to 3.0 fmol/mg of protein. Thus, high concentra-
tions of PgR exist in benign liver tumors or hepatoblastoma, but not in HCC. At
present, it is not known why most HCCs are negative for PgR or the titer is so low if
present at all.
Operatioe Results ofHCC
In our series of 107 radical hepatic resections, the 1-, 3-, and 5-year survival rates in
male and female patients were 78% and 70%, 45% and 52%, and 19% and 52%,
respectively38. The difference was significant 47 months after operation. The
clinicopathologic background was not different between men and women.
Thereafter, we have analyzed the recurrence and survival rates between the
patients with AR-negative and AR-positive HCCs39. The recurrence rates were
33.8% in the former and 67.9% in the latter group. Also, the 5-year survival rate
was significantly better in the patients with AR-negative HCCs (62.2%) than in the
patients with the positive tumors (17.3%). On the other hand, the presence or
absence of ER in HCC did not influence the long term results4.
Hormone Therapy ofHCC
Friedman et al.
22 first tried hormone therapy for HCC. Since in hormone-
responsive tissue such as breast or endometrial carcinoma that contains ERs,
administration of progestins results in decreased ER titers and often causes tumor
regression, they performed progestin therapy in 5 patients with HCC. Tumor
regression was observed in two of them. We have treated 9 patients with nonresec-
table HCC with tamoxifen, but no apparent tumor response was found (unpub-
lished data). As tamoxifen inhibits the development of hyperplastic nodules in the4 N. NAGASUE AND H. KOHNO
liver of experimental animals4, anti-estrogen therapy may be effective in selected
patients with HCC. However, we probably cannot expect so much solely by anti-
estrogen therapy in the treatment of far advanced HCCs. Based upon the fact that
human HCCs contain AR, Forbes et al.
42 performed anti-androgen therapy with
cyproterone acetate. They have found objective responses in 5 of 25 patients with
advanced HCCs. We have also obtained a similar but a little worse result in patients
with nonresectable or recurrent HCCs (unpublished data). Recently, Bannister et
al.
43 and more recently Ostrowski eta/. 44 reported that the development of HCC is
strongly related to the increased hepatic AR concentrations in diethylnitrosamine
induced hepatocarcinogenesis in rats. Using human HCC cell lines, Ohnishi et al.
5
have shown that the growth ofAR positive cells was enhanced by dihydrotestoster-
one, and was inhibited by adding cyproterone acetate.
Future Perspective
Except for oral contraceptive-associated HCCs which may be highly estrogen-
dependent, human HCCs seem to be more androgen-dependent. Male predomi-
nance, the receptor profiles, and the clinical evidence may support this speculation.
Routine receptor assays of surgically removed specimens will be useful for further
elucidation of this unsolved problem. Based upon the receptor result in each
individual, appropriate hormone therapy which may be anti-androgenic, anti-
estrogenic, or both will be possible. The poor survival in men after liver resection
could theoretically be improved by adjuvant anti-androgen therapy. It may be
possible to improve the survival rate of those with nonresectable HCCs by
combining hormone therapy with conventional chemo- or immuno-chemotherapy.
If hormonal manipulation can prevent the development of HCC in high-risk
patients will be a matter for future work.
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